Lloyd Wei Tat Tang

Dr. Lloyd Wei Tat Tang

Pharmacy, National University of Singapore, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang
RVRavi Kumar Verma
Ravi Kumar Verma
HFHao Fan
Hao Fan
ECEric Chun Yong Chan
Eric Chun Yong Chan
Benzbromarone (BBR), a potent uricosuric agent for the management of gout, is known to cause fatal fulminant hepatitis. While the mechanism of BBR-induced idiosyncratic hepatotoxicity remains unelucidated, cytochrome P450 enzyme (CYP450)-mediated bioactivation of BBR to electrophilic reactive metabolites is commonly regarded as a key molecular-initiating event. However, apart from causing aberrant toxicities, reactive metabolites may result in mechanism-based inactivation (MBI) of CYP450. Here, we investigated and confirmed that BBR inactivated CYP3A4 in a time-, concentration- and NADPH-dependent manner with KI, kinact and partition ratio of 11.61 µM, 0.10 min-1 and 110 respectively. Co-incubation with ketoconazole, a competitive inhibitor of CYP3A4, attenuated the MBI of CYP3A4 by BBR while the presence of glutathione and catalase did not confer such protection. The lack of substantial recovery of enzyme activity post-dialysis and following oxidation with potassium ferricyanide, combined with the absence of a Soret peak in spectral difference scans implied that MBI of CYP3A4 by BBR did not occur through the formation of quasi-irreversible metabolite-intermediate complexes. Analysis of the reduced CO-difference spectrum revealed a ~44% reduction in ferrous-CO binding and hinted that inactivation is mediated via irreversible covalent adduction to both the prosthetic heme moiety and the apoprotein. Finally, our in silico covalent docking analysis further suggested the modulation of substrate binding to CYP3A4 via the covalent adduction of epoxide-derived reactive intermediates of BBR to two key cysteine residues (Cys239 and Cys58) vicinal to the entrance of the orthosteric binding site. Significance Statement While the bioactivation of benzbromarone (BBR) to reactive metabolites has been well characterized, its potential to cause mechanism-based inactivation (MBI) of CYP450 has not been fully investigated. Here, we report the MBI of CYP3A4 by BBR via irreversible covalent adduction and developed a unique covalent docking methodology to predict the structural molecular determinants underpinning the inactivation for the first time. Our findings lay the groundwork for future investigation of clinically-relevant drug-drug interactions implicating BBR and mechanisms of BBR-induced idiosyncratic hepatotoxicity.

1 September 2021 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang
JTJian Wei Teng
Jian Wei Teng
RVRavi Kumar Verma
Ravi Kumar Verma
SKSiew Kwan Koh
Siew Kwan Koh
LZLei Zhou
Lei Zhou
ECEric Chun Yong Chan
Eric Chun Yong Chan
Infigratinib (INF) is a promising selective inhibitor of fibroblast growth factor receptors 1–3 that has recently been accorded both orphan drug designation and priority review status by the US Food and Drug Administration for the treatment of advanced cholangiocarcinoma. Its propensity to undergo bioactivation to electrophilic species was recently expounded upon. However, other than causing aberrant idiosyncratic toxicities, these reactive intermediates may elicit mechanism-based inactivation of cytochrome P450 enzymes. In this study, we investigated the interactions between INF and the most abundant hepatic CYP3A. Our findings revealed that, apart from being a potent noncompetitive reversible inhibitor of CYP3A4, INF inactivated CYP3A4 in a time-, concentration- and NADPH-dependent manner with inactivator concentration at half-maximum inactivation rate constant, maximum inactivation rate constant, and partition ratio of 4.17 µM, 0.068 minute−1, and 41, respectively, when rivaroxaban was employed as the probe substrate. Coincubation with testosterone (alternative CYP3A substrate) or ketoconazole (direct CYP3A inhibitor) attenuated the rate of inactivation, whereas the inclusion of glutathione and catalase did not confer such protection. The lack of enzyme activity recovery after dialysis for 4 hours and oxidation with potassium ferricyanide, coupled with the absence of the characteristic Soret peak signature collectively substantiated that inactivation of CYP3A4 by INF was not mediated by the formation of quasi-irreversible metabolite-intermediate complexes but rather through irreversible covalent adduction to the prosthetic heme and/or apoprotein. Finally, glutathione trapping and high-resolution mass spectrometry experimental results unraveled two plausible bioactivation mechanisms of INF arising from the generation of a p-benzoquinonediimine and epoxide reactive intermediate. SIGNIFICANCE STATEMENT The potential of INF to cause MBI of CYP3A4 was unknown. This study reports the reversible noncompetitive inhibition and irreversible covalent MBI of CYP3A4 by INF and proposes two potential bioactivation pathways implicating p-benzoquinonediimine and epoxide reactive intermediates, following which a unique covalent docking methodology was harnessed to elucidate the structural and molecular determinants underscoring its inactivation. Findings from this study lay the groundwork for future investigation of clinically relevant drug-drug interactions between INF and concomitant substrates of CYP3A4.

23 June 2025 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
AHAki T. Heikkinen
Aki T. Heikkinen
MMMailys De Sousa Mendes
Mailys De Sousa Mendes
MWMark A. West
Mark A. West
SYSook Wah Yee
Sook Wah Yee
IGIain Gardner
Iain Gardner
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang

25 September 2024 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang
KLKimberly Lapham
Kimberly Lapham
TGTheunis C. Goosen
Theunis C. Goosen

18 June 2024 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang
YSYuanyuan Shi
Yuanyuan Shi
RSRaman Sharma
Raman Sharma
ROR. Scott Obach
R. Scott Obach
The propensity for aldehyde oxidase (AO) substrates to be implicated in drug-drug interactions (DDI) is not well-understood due to the dearth of potent inhibitors that elicit in vivo inhibition of AO. While there is only one reported instance of DDI that has been ascribed to the inhibition of AO to-date, the supporting evidence for this clinical interaction is rather tenuous and its veracity has been called into question. Our group recently reported that the epidermal growth factor receptor inhibitor erlotinib engendered potent time-dependent inhibition of AO with inactivation kinetic constants in the same order of magnitude as its free circulating plasma concentrations. At the same time, it was previously reported that the concomitant administration of erlotinib with the investigational drug OSI-930 culminated in a ~2-fold increase in its systemic exposure. Although the basis underpinning this interaction remains unclear, the structure of OSI-930 contains a quinoline motif which is amenable to oxidation at the electrophilic carbon adjacent to the nitrogen atom by molybdenum-containing hydroxylases like AO. In this study, we conducted metabolite identification which revealed that OSI-930 undergoes AO metabolism to a mono-oxygenated 2-oxo metabolite and assessed its formation kinetics in human liver cytosol. Additionally, reaction phenotyping in human hepatocytes revealed that AO contributes nearly ~50% to the overall metabolism of OSI-930. Finally, modelling the interaction between erlotinib and OSI-930 using a mechanistic static model projected an ~1.85-fold increase in the systemic exposure of OSI-930 - which accurately recapitulated clinical observations. Significance Statement In this study, we delineate an AO metabolic pathway in the investigational drug OSI-930 for the first time and confirmed that it represented a major route of metabolism through reaction phenotyping in human hepatocytes. Our study provided compelling mechanistic and modelling evidence for the first instance of an AO-mediated clinical DDI stemming from the in vivo inhibition of the AO-mediated quinoline 2-oxidation pathway in OSI-930 by erlotinib.

2 April 2024 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
LTLloyd Wei Tat Tang
Lloyd Wei Tat Tang
EDEthan DaSilva
Ethan DaSilva
KLKimberly Lapham
Kimberly Lapham
ROR. Scott Obach
R. Scott Obach
Aldehyde oxidase (AO) is a molybdenum cofactor-containing cytosolic enzyme that has gained prominence due to its involvement in the developmental failure of several drug candidates in first-in-human trials. Unlike cytochrome P450s (P450) and glucuronosyltransferase, AO substrates have been plagued by poor in vitro to in vivo extrapolation, leading to low systemic exposures and underprediction of human dose. However, apart from measuring a drug9s AO clearance rates, it is also important to determine the relative contribution to metabolism by this enzyme (fm,AO). Although hydralazine is the most well-studied time-dependent inhibitor (TDI) of AO and is frequently employed for AO reaction phenotyping in human hepatocytes to derive fm,AO, multiple studies have expressed concerns pertaining to its utility in providing accurate estimates of fm,AO values due to its propensity to significantly inhibit P450s at the concentrations typically utilized for reaction phenotyping. In this study, we characterized icotinib, a cyclized analogue of erlotinib, as a potent TDI of AO - inactivating human liver cytosolic zoniporide 2-oxidation equipotently with erlotinib with a kinact/KI ratioof 463 and 501 min-1mM-1, respectively. Moreover, icotinib also exhibits selectivity against P450 and elicits significantly weaker inhibition against human liver microsomal UGT1A1/3 as compared to erlotinib. Finally, we evaluated icotinib as an inhibitor of AO for reaction phenotyping in cryopreserved human hepatocytes and demonstrated that it can yield more accurate prediction of fm,AO compared to hydralazine and induce sustained suppression of AO activity at higher cell densities - which will be important for reaction phenotyping endeavors of low clearance drugs. Significance Statement In this study, we characterized icotinib as a potent time-dependent inhibitor of AO with ample selectivity margins against the P450s and UGT1A1/3 and demonstrated its utility for reaction phenotyping in human hepatocytes to obtain accurate estimates of fm,AO for victim DDI risk predictions. We envisage the adoption of icotinib in place of hydralazine in AO reaction phenotyping.